Skip to Main Content

Paper Details

Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer.
J Immunother Cancer
1
2023
CD27, CD4, CD8, Cisplatin, DDFTFS, Neoantigen, T cell, autologous antigen-presenting cells, cisplatin, gemcitabine, ipilimumab, metastatic urothelial cancer, patient, patients, peripheral blood CD4 and CD8 T cells, tumor
Author NameAffiliation
Seunghee Kim-SchulzeTisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Seunghee Kim-SchulzeIcahn School of Medicine at Mount Sinai
Seunghee Kim-SchulzeTisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Seunghee Kim-SchulzeIcahn School of Medicine at Mount Sinai
Andrew V Uzilov
Robert Sebra
Robert SebraIcahn School of Medicine at Mount Sinai
Robert Sebra
Robert SebraIcahn School of Medicine at Mount Sinai
Sacha GnjaticMount Sinai School of Medicine
Sacha GnjaticTisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Sacha GnjaticIcahn School of Medicine at Mount Sinai
Sacha GnjaticMount Sinai School of Medicine
Sacha GnjaticTisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Sacha GnjaticIcahn School of Medicine at Mount Sinai
Matthew D GalskyMount Sinai School of Medicine
Matthew D GalskyTisch Cancer Institute, Icahn School of Medicine at Mount Sinai
  • 1 - 17

Datasets

Release 1.2